What a controversial drug approval could mean for future Alzheimer's treatments
- A controversial Alzheimer's drug approval poses some big challenges for the future of the field;
- We chronicled the history of Noom, which raised $540 million from top investors after spending a decade trying to crack the weight-loss app business;
- Amazon and Walmart face off on discounting prescriptions.
We're still looking for nominees for our annual 30 under 40 list!
Know someone under 40 transforming the healthcare industry? Submit their name here. Nominations are due by June 30.
the Food and Drug Administration approved the first new Alzheimer's treatment in nearly two decades.
There were a few surprises that came with the approval of the drug, Aduhelm. For one, there were no real limitations placed by FDA on who will be eligible for the new drug. And the drug costs roughly $56,000 a year..... And let's not forget this is a drug that an expert panel voted against approving last November. Allison DeAngelis and Shelby Livingston this week dug into a little-known barrier could stand in the way of millions of patients clamoring to get the treatment.
Since the approval, doctors have started resigning from the FDA's expert panel - the one that voted against approving the drug.
Allison and Andrew Dunn analyzed the problems facing Aduhelm - and future Alzheimer's drugs.
The first new Alzheimer's drug in decades costs $56,000, probably doesn't work, and could stand in the way of better treatments
This week, Megan Herbroth and Gabby Landsverk went digging into
The weight-loss startup stunned the healthcare industry in May when it raised $540 million from investors including Silver Lake and Oak HC/FT. And it's betting big that it can do for sleep and anxiety what it did for weight loss.It's taken 13 years to get to this point, and not every idea worked.
Inside the rise of $3.7 billion Noom: How a 13-year-old weight-loss startup is taking on one of the fastest-growing markets in digital health
Is it just me, or has a lot of news about the health ambitions of
And prescriptions isn't the only place where competition between the two retail giants is heating up. Both are beefing up their virtual care presence. Last Friday, Shelby had the scoop that Walmart quietly filed to be a provider in 16 new states.In a rare public appearance, a top Amazon VP shared that Amazon's medical service will announce multiple companies it's working with in the next few months. When it comes to prescriptions, the two have the potential to shake up the
Amazon and Walmart are competing to offer you the cheapest prescriptions, and it could shake up the entire pharmacy industry
More stories we covered this week:
- The biggest deal news this week came from One Medical's plans to acquire Iora Health for $2.1 billion. Read our full story on the deal here.
- Transcarent, a startup backed by Livongo veterans, raised $58 million at a nearly $500 million valuation.
- In our first in a series called "Future of Healthcare," we detailed 3 key challenges facing telehealth.
- We tallied up the 9 biggest biotech winners after the FDA took an entirely new approach to approve Biogen's Alzheimer's drug.
- Delhi reports its lowest daily COVID-19 cases in 104 days, records 213 single day COVID-19 cases
- Here’s how to recharge your Reliance Jio on WhatsApp
- India may classify Bitcoin as an asset class, but that may not solve the underlying problem
- Facebook rolls out new chat themes and payment options in Messenger app for US users
- Dodla Dairy's ₹520 crore IPO isn't to expand into new markets but to strengthen its foothold where it already exists